| 04/22/2026 3:01 PM | Keros Therapeutics (1664710) Filer | Form DEF 14A | |
| 04/22/2026 3:03 PM | Keros Therapeutics (1664710) Filer | Form DEFA14A | |
| 04/17/2026 3:15 PM | BIENAIME JEAN JACQUES (1221590) Reporting Keros Therapeutics (1664710) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/07/2026 11:39 AM | BlackRock, Inc. (2012383) Filed by Keros Therapeutics (1664710) Subject | Form SCHEDULE 13G | |
| 04/06/2026 3:15 PM | Keros Therapeutics (1664710) Issuer Seehra Jasbir (1732369) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 8:57 PM | Keros Therapeutics (1664710) Subject ORBIMED ADVISORS LLC (1055951) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/27/2026 3:15 PM | Cho Esther (2081460) Reporting Keros Therapeutics (1664710) Issuer | Form 4/A | |
| 03/11/2026 3:33 PM | BIENAIME JEAN JACQUES (1221590) Reporting Keros Therapeutics (1664710) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/11/2026 3:37 PM | Keros Therapeutics (1664710) Issuer Newton Charles W. (1866219) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/11/2026 3:39 PM | Keros Therapeutics (1664710) Issuer Newton Charles W. (1866219) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/09/2026 7:01 AM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for KROS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/26/2026 3:02 PM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/20/2026 3:15 PM | Keros Therapeutics (1664710) Issuer Regnante Keith (1682068) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/20/2026 3:15 PM | Cho Esther (2081460) Reporting Keros Therapeutics (1664710) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/20/2026 3:15 PM | Keros Therapeutics (1664710) Issuer Lerner Lorena Raquel (2081359) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/20/2026 3:15 PM | Keros Therapeutics (1664710) Issuer Seehra Jasbir (1732369) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/18/2026 3:02 PM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/09/2026 3:15 PM | Keros Therapeutics (1664710) Issuer Seehra Jasbir (1732369) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 3:16 PM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/18/2025 3:34 PM | Keros Therapeutics (1664710) Issuer ORBIMED ADVISORS LLC (1055951) Reporting OrbiMed Capital GP VII LLC (1760648) Reporting OrbiMed Genesis GP LLC (1808744) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:27 PM | GORDON CARL L (1282930) Reporting Keros Therapeutics (1664710) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:15 PM | Keros Therapeutics (1664710) Issuer Knowles Julius (1808365) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/19/2025 5:19 AM | Keros Therapeutics (1664710) Subject | Form SC TO-I/A | |
| 11/18/2025 3:07 PM | ExodusPoint Capital Management, LP (1736225) Filed by Keros Therapeutics (1664710) Subject | Form SCHEDULE 13G | |
| 10/27/2025 3:05 PM | D. E. SHAW & CO, L.P. (1009268) Filed by Keros Therapeutics (1664710) Subject | Form SCHEDULE 13G | |
| 10/22/2025 8:26 PM | Keros Therapeutics (1664710) Subject TANG CAPITAL MANAGEMENT LLC (1232621) Filed by | Form SCHEDULE 13G | |
| 10/20/2025 5:09 AM | Keros Therapeutics (1664710) Subject | Form SC TO-I | |
| 10/17/2025 4:53 PM | Kariv Tomer (1568077) Reporting Keros Therapeutics (1664710) Issuer Nussbaum Ran (1609805) Reporting Pontifax (0) Israel Pontifax Late Stage Fund L.P. (1793769) Reporting Pontifax Late Stage GP Ltd. (1793770) Reporting Pontifax Management 4 G.P. (2015) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/16/2025 4:36 PM | Keros Therapeutics (1664710) Subject Pontifax Management 4 G.P. (2015) Filed by | Form SCHEDULE 13D/A | |
| 10/15/2025 12:24 PM | ADAR1 Capital Management GP, LLC (1940267) Reporting ADAR1 Capital Management, LLC (1940272) Reporting ADAR1 Partners, LP (1758866) Reporting Keros Therapeutics (1664710) Issuer Schneeberger Daniel (1861120) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/15/2025 5:50 AM | ADAR1 Capital Management, LLC (1940272) Filed by Keros Therapeutics (1664710) Subject | Form SCHEDULE 13D/A | |
| 10/15/2025 5:40 AM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/15/2025 5:42 AM | Keros Therapeutics (1664710) Subject | Form SC TO-C | |
| 09/12/2025 3:45 PM | Keros Therapeutics (1664710) Subject Rovaldi Christopher (1706040) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/08/2025 7:02 AM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/05/2025 3:10 PM | Keros Therapeutics (1664710) Issuer Seehra Jasbir (1732369) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/21/2025 3:15 PM | ADAR1 Capital Management, LLC (1940272) Filed by Keros Therapeutics (1664710) Subject | Form SCHEDULE 13D/A | |
| 08/20/2025 8:50 AM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/15/2025 3:32 PM | Cho Esther (2081460) Reporting Keros Therapeutics (1664710) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 08/15/2025 3:34 PM | Keros Therapeutics (1664710) Issuer Lerner Lorena Raquel (2081359) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 07/17/2025 7:03 AM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
|
| 06/24/2025 3:05 PM | ADAR1 Capital Management GP, LLC (1940267) Reporting ADAR1 Capital Management, LLC (1940272) Reporting ADAR1 Partners, LP (1758866) Reporting Keros Therapeutics (1664710) Issuer Schneeberger Daniel (1861120) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/12/2025 3:51 PM | ADAR1 Capital Management GP, LLC (1940267) Reporting ADAR1 Capital Management, LLC (1940272) Reporting ADAR1 Partners, LP (1758866) Reporting Keros Therapeutics (1664710) Issuer Schneeberger Daniel (1861120) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2025 6:45 AM | Kariv Tomer (1568077) Reporting Keros Therapeutics (1664710) Issuer | Form 4/A | |
| 06/11/2025 6:30 AM | Keros Therapeutics (1664710) Issuer Nussbaum Ran (1609805) Reporting | Form 4/A | |
| 06/09/2025 5:56 AM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/06/2025 3:15 PM | BIENAIME JEAN JACQUES (1221590) Reporting Keros Therapeutics (1664710) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 3:15 PM | GRAY MARY ANN (1261974) Reporting Keros Therapeutics (1664710) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 3:15 PM | Keros Therapeutics (1664710) Issuer Seth Alpna (1721020) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 3:15 PM | Keros Therapeutics (1664710) Issuer Nussbaum Ran (1609805) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 3:15 PM | Kariv Tomer (1568077) Reporting Keros Therapeutics (1664710) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 3:15 PM | Farzan Nima (1808296) Reporting Keros Therapeutics (1664710) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 3:15 PM | GORDON CARL L (1282930) Reporting Keros Therapeutics (1664710) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 3:15 PM | Keros Therapeutics (1664710) Issuer Knowles Julius (1808365) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2025 5:58 AM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/27/2025 12:49 PM | Keros Therapeutics (1664710) Filer | Form DEFA14A | |
| 05/19/2025 7:00 AM | Keros Therapeutics (1664710) Filer | Form DEFA14A | |
| 05/19/2025 7:01 AM | Keros Therapeutics (1664710) Filer | Form DEFA14A | |
| 05/19/2025 7:02 AM | Keros Therapeutics (1664710) Filer | Form DEFA14A | |
| 05/14/2025 4:49 PM | Keros Therapeutics (1664710) Subject Madison Avenue Partners, LP (1801265) Filed by | Form SCHEDULE 13G | |
| 05/12/2025 10:29 AM | ADAR1 Capital Management, LLC (1940272) Filed by Keros Therapeutics (1664710) Subject | Form SCHEDULE 13D/A | |
| 05/12/2025 7:01 AM | Keros Therapeutics (1664710) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |